Skip to main content
Equibles
BBOT logo

BBOT · BridgeBio Oncology Therapeutics, Inc.

Track BBOT — free

Use BBOT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BBOT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.60 -0.29 (-7.46%) At close · Oct 5
Rebalance outlook locked
Market Cap
$314.28M
Shares
80.17M
Volume · Oct 5 481.65K Avg daily vol (3M) 467.53K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.60 Open$3.88 Day$3.58–3.88 52W close$3.60–13.73 Avg vol 30d648K Short int3.6M · 4.5% float · 4.4d Short vol67% Last earningsJan 7, 2026 DataFeb 2024–Oct 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$182.11M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-48.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$225.71M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+59.5%
Year over year · more shares
Price change (1Y)
-68.7%
Trailing year
Short interest
4.5%
Latest settlement · 4.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −60%
below
Price vs 50-day avg −50%
below
RSI (14) 19
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −60%
trailing
6-month return −61%
trailing
YTD return −71%
this year
Relative strength −72%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $7 › 200d $9 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +16 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.49% of float · ▼ -41.9% MoM · 4.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
65 holders — near 2-yr high, broad support
Squeeze score 47
elevated · 0–100
Fundamentals
Fair
EPS growth +100%
Y/Y
Free cash flow $-114.5M
Quant / Vol
risk profile
Very High
Volatility 70%
annualized · 1-yr
Max drawdown −74%
past year
ATR 10.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−60% Bearish
Price vs 50-day avg
−50% Bearish
RSI (14)
19 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $9 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +16 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.49% of float · ▼ -41.9% MoM · 4.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
65 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $4 · 0% Range high $14
vs 200-day avg -60% vs 50-day avg -50%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BBOT
BridgeBio Oncology Therapeutics, Inc.
this stock
$314.28M -71.2% — — 4.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
65
% held
73.7%
Net QoQ
+1.7M sh
Top holder
Cormorant Asset Managemen…
Held Float
View
Held by Funds
Fund positions
45
View
Short & Settlement
Short Interest Falling
Shares short
3.6M
Days to cover
4.4d
Change
-2.6M sh
View
Short Volume
Short vol %
67%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
3
Value
$20
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
40.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-134.0M
EPS diluted
$-4.30
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 8, 2026
This year
13
View
Earnings & Events
Webcasts
Last webcast
Jan 7, 2026
View

Performance

5D 20D 120D MTD YTD
BBOT -5.5% -59.9% -60.8% -12.2% -71.3%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -6.7% -60.5% -72.4% -13.8% -84.9%
Key facts CIK 1869105 CUSIP 107924102 13F (30d) 2 filings 2 filers Visit website Investor relations